Comfort Ii Trial

Comfort ii controlled myelofibrosis study with oral jak inhibitor treatment ii was a randomized open label phase 3 study with 219 patients with intermediate 2 risk or high risk myelofibrosis.

Comfort ii trial. Jakavi was studied in the most comprehensive clinical trial program in myelofibrosis to date 1 2 comfort ii. Open label randomised phase iii study versus bat 2 3 real world comparator study bat included any single treatment or combination of treatments 2 4. 1 2 the study plan included follow up of patients receiving jakafi at 3 and 5 years 3 4.

3 patients n 219 were randomized 2 1 to receive ruxolitinib 15 or 20 mg twice. Controlled myelofibrosis study with oral janus associated kinase jak inhibitor treatment ii. Comfort ii was a randomized 2 1 open label phase 3 study in patients with myelofibrosis.

Patients randomized to bat could crossover to ruxolitinib upon protocol defined disease progression or after the primary end point confounding long term comparisons. Randomized double blind study comparing patient comfort and safety between iodixanol 320 mg i ml and iopamidol 370 mg i ml in patients undergoing peripheral arteriography the comfort ii trial. Ruxolitinib is a janus kinase jak jak1 jak2 inhibitor that has demonstrated superiority over placebo and best available therapy bat in the controlled myelofibrosis study with oral jak inhibitor treatment comfort studies.

The comfort ii trial is an open label phase 3 study that includes patients with a diagnosis of primary mf pmf post polycythemia vera mf ppv mf or postessential thrombocythemia mf pet mf by world health organization and international working group for myelofibrosis research and treatment criteria 9 10 classified as intermediate 2 or high risk using the international prognostic scoring system ipss.